| 吴慧芳1 王海琳2△.卵巢癌的靶向药物治疗研究进展[J].,2012,12(6):1195-1197 |
| 卵巢癌的靶向药物治疗研究进展 |
| Targeted Drug in Ovarian Cancer |
| |
| DOI： |
| 中文关键词: 卵巢癌 靶向药物 治疗 |
| 英文关键词: Ovarian cancer Targeted Drug Therapy |
| 基金项目: |
|
| 摘要点击次数: 799 |
| 全文下载次数: 2921 |
| 中文摘要: |
| 卵巢癌死亡率居女性生殖系统恶性肿瘤之首，早期诊断困难，晚期患者治疗效果差，分子靶向药物成为近年的研究热点。目
前许多靶向药物已经进入临床试验阶段，给卵巢癌特别是术后复发及化疗耐药患者的治疗带来新的希望。本文主要对单克隆抗
体，酪氨酸激酶抑制剂等几种药物在卵巢癌的研究进行综述。 |
| 英文摘要: |
| Ovarian cancer is the first leading cause of death among gynecologic malignancies. It is difficult to diagnose early and
often had bad therapeutic effect at later period. So molecule targeted drug becomes the focus in recent years of research. At present, many
molecule targeted drugs has been gaining interest and already made impressive progress in both the pre-clinical and clinical settings,
bring new hopes for patients with ovarian cancer, especially for patients with recurrent and chemotherapy resistant cancers. This paper
mainly reviews the recent achievements in the development of Monoclonal Antibodies and tyrosine kinase inhibitor for ovarian cancer
therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
